Income Statement
ADC THERAPEUTICS SA
ADCT
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Revenue
|
81.36 | 70.84 | 69.56 |
|
Cost of Revenue
|
5.80 | 5.95 | 2.53 |
|
Gross Profit
|
75.56 | 64.89 | 67.03 |
|
Operating Expenses
|
140.56 | 151.53 | 175.55 |
|
Research & Development
|
104.01 | 109.63 | 127.13 |
|
Selling, General & Administrative
|
43.37 | 44.02 | 57.46 |
|
Other Operating Expenses
|
- | - | - |
|
Operating Income
|
-65.01 | -86.64 | -108.52 |
|
Non-Operating Income
|
-20.11 | -25.48 | -29.43 |
|
Interest Income
|
8.81 | 12.30 | 10.54 |
|
Interest Expense
|
16.30 | 50.21 | 46.33 |
|
Other Non-Op Income / Expense
|
22.71 | -1.54 | -5.53 |
|
Income Before Tax
|
-141.61 | -156.14 | -195.42 |
|
Income Tax Expense
|
1.02 | 1.71 | 44.63 |
|
Non-Controlling Interest
|
- | - | - |
|
Net Income
|
-142.62 | -157.85 | -240.05 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - |
|
EBITDA
|
-65.01 | -86.64 | -108.52 |
|
Earnings Per Share (Basic)
|
-1.12 | -1.62 | -2.94 |
|
Diluted EPS
|
-1.12 | -1.62 | -2.94 |
|
Weighted Average Shares
|
127.07 | 97.16 | 81.71 |
|
Diluted Weighted Avg Shares
|
127.07 | 97.16 | 81.71 |
|
Comprehensive Income
|
-141.72 | -1.33 | -1.92 |